



**Commercial/Healthcare Exchange PA Criteria**  
***Effective: March 2008***

**Prior Authorization:** Remodulin

**Products Affected:** Remodulin (treprostinil) injection

**Medication Description:** Treprostinil is a direct vasodilator of both pulmonary and systemic arterial vascular beds; also inhibits platelet aggregation.

**Covered Uses:**

1. Treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise.
2. Treatment of pulmonary arterial hypertension (PAH) in patients requiring transition from epoprostenol.

**Exclusion Criteria:** N/A

**Required Medical Information:**

1. Diagnosis
2. New York Heart Association classification
3. World Health Organization (WHO) functional class
4. Previous therapies tried/failed

**Age Restrictions:** N/A

**Prescriber Restrictions:** Prescribed by, or in consultation with, a pulmonologist or a cardiologist

**Coverage Duration:** 12 months

**Other Criteria:**

**Pulmonary arterial hypertension (PAH)**

1. Patient has Who Group 1 PAH;**AND**
2. Patient exhibits New York Heart Association Class II to IV symptoms; **AND**
3. Patient has had an intolerance to, or treatment failure of a calcium channel blocker after favorable response to acute vasoreactivity testing **OR** failure to have a pulmonary vasodilator response to an acute challenge of a short acting vasodilator; **AND**
4. Patient has tried and failed, or has an intolerance to, contraindication\*, or treatment failure to Tracleer (bosentan).

**Pulmonary arterial hypertension in patients transitioning from epoprostenol**

1. Patient has Who Group 1 PAH;**AND**
2. Patient exhibits New York Heart Association Class II to IV symptoms

Last Res.September 2020



Confidential Information

This document is confidential and proprietary to ConnectiCare. Unauthorized use and distribution are prohibited.

**References:**

1. Remodulin (treprostinil) [prescribing information]. Research Triangle Park, NC: United Therapeutics Corp; September 2020.

**Policy Revision history**

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	Update	<p>Adopted EH template</p> <p>Removed from PAH CCI policy, previous revision history: 3/08, 6/10, 5/16, 11/12, 11/16, 11/17, 9/18, 11/18, 9/18, 10/18, 5/19</p> <p>Removed Other Criteria: Patient exhibits New York heart association (NYHA) Class II or IV symptoms</p> <p>Added indication: Pulmonary arterial hypertension in patients transitioning from epoprostenol</p>	All	9/22/2020